Price action is getting interesting, and the setup looks like it could be building toward a breakout. Volume and momentum are the things I’m watching closely here.
Not saying it’s guaranteed to run, small caps can move violently in either direction, but BAOS definitely looks like one worth keeping on the radar.
Let’s see if the volume comes in and confirm the move. 👀📈
On August 14, 2026, Quantum BioPharma Ltd. filed a Form 6-K with the SEC, providing its financial and operational results for the second quarter ended June 30, 2026. The company reported a strengthened balance sheet, with combined cash, cash equivalents, and digital assets totaling approximately US$9.5 million, up from US$4.1 million at the end of 2025. Specifically, cash and cash equivalents nearly doubled to US$3.65 million. Management noted a disciplined reduction in costs, with total operating expenses falling 53% year-over-year to US$2.29 million, and cash used in operating activities decreasing 44% to US$3.46 million for the first half of 2026. Based on these metrics, the company projects sufficient liquidity to fund operations through at least October 2027. Operationally, the filing highlights a significant regulatory milestone: on August 10, 2026, the FDA approved the company’s Investigational New Drug application for Lucid-MS, allowing the firm to initiate a Phase 2 clinical trial for progressive multiple sclerosis. The submission includes a press release as Exhibit 99.1 detailing these financial improvements and the advancement of its neuroprotective clinical program.
On August 14, 2026, Quantum BioPharma Ltd. filed a Form 6-K with the SEC, providing its financial and operational results for the second quarter ended June 30, 2026. The company reported a strengthened balance sheet, with combined cash, cash equivalents, and digital assets totaling approximately US$9.5 million, up from US$4.1 million at the end of 2025. Specifically, cash and cash equivalents nearly doubled to US$3.65 million. Management noted a disciplined reduction in costs, with total operating expenses falling 53% year-over-year to US$2.29 million, and cash used in operating activities decreasing 44% to US$3.46 million for the first half of 2026. Based on these metrics, the company projects sufficient liquidity to fund operations through at least October 2027. Operationally, the filing highlights a significant regulatory milestone: on August 10, 2026, the FDA approved the company’s Investigational New Drug application for Lucid-MS, allowing the firm to initiate a Phase 2 clinical trial for progressive multiple sclerosis. The submission includes a press release as Exhibit 99.1 detailing these financial improvements and the advancement of its neuroprotective clinical program.
Title
Purchased 15k shares at 2.57 and 5k shares at 2.22
This seems like an extremely good opportunity for generational wealth. Lets go!!
Ill be starting from Colombo and want to drive through some beautiful nature spots. Any suggestions?
A new IBRK user and i need some advice on this and also the bank charges please. Thanks